RxDoctor Payments Data

Michael Turner, MD

Internal Medicine · Calera, ALNPI 1700856770

Payments from drug & device makers

$10,733in general payments, 2019–2025

Across 709 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Johnson & Johnson$989
  • GSK$810
  • Boehringer Ingelheim$785
  • Novo Nordisk$730
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$10,65499%
  • Education$200%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,733 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$76,416
Medicare patients
105
Services billed
1,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin210$226,783
MounjaroTirzepatide151$209,729
OzempicSemaglutide139$162,789
EliquisApixaban134$119,184
LinzessLinaclotide73$68,374
KerendiaFinerenone50$63,286
XareltoRivaroxaban51$49,984
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$47,791
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$47,518
RybelsusSemaglutide27$41,305
FarxigaDapagliflozin Propanediol33$36,353
TrulicityDulaglutide27$28,414
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$26,653
VraylarCariprazine Hcl13$21,222
Breo ElliptaFluticasone/Vilanterol40$19,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$785$238,907223 claims
Lilly USA, LLCMounjaro, Trulicity$727$238,143178 claims
Novo NordiskOzempic, Rybelsus$730$204,094166 claims
PfizerEliquis$342$119,184134 claims
AbbVieLinzess, Vraylar$1,400$89,59686 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,210$84,14480 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$810$77,703113 claims
BayerKerendia$504$63,28650 claims
Johnson & JohnsonXarelto$989$49,98451 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$287$18,09626 claims
MerckJanuvia$94$17,44811 claims
NovartisEntresto$107$12,39616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Calera

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →